Pisick, E. P., Garrett-Mayer, E., Halabi, S., Mangat, P. K., Yang, E.-H., Dib, E. G., … Schilsky, R. L. (2020). Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Pisick, Evan P., Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Eddy Shih-Hsin Yang, Elie G. Dib, Earle Frederick Burgess, et al. “Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Pisick EP, Garrett-Mayer E, Halabi S, Mangat PK, Yang ES-H, Dib EG, et al. Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Pisick, Evan P., et al. “Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Pisick EP, Garrett-Mayer E, Halabi S, Mangat PK, Yang ES-H, Dib EG, Burgess EF, Zakem MH, Rohatgi N, Bilen MA, Warren SL, Anderson ST, Rygiel AL, Schilsky RL. Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JOURNAL OF CLINICAL ONCOLOGY. 2020.